S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:ADVM

Adverum Biotechnologies Competitors

$10.96
-0.34 (-3.01 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.59
Now: $10.96
$11.86
50-Day Range
$11.30
MA: $12.92
$14.36
52-Week Range
$7.36
Now: $10.96
$26.98
Volume1.35 million shs
Average Volume849,827 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.72

Competitors

Adverum Biotechnologies (NASDAQ:ADVM) Vs. BEAM, RLAY, SWTX, RVMD, NK, and EDIT

Should you be buying ADVM stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Adverum Biotechnologies, including Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), NantKwest (NK), and Editas Medicine (EDIT).

Adverum Biotechnologies (NASDAQ:ADVM) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares Adverum Biotechnologies and Beam Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85
Beam Therapeutics$20,000.00212,996.07$-78,330,000.00($14.05)-5.23

Adverum Biotechnologies has higher revenue and earnings than Beam Therapeutics. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adverum Biotechnologies and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Institutional & Insider Ownership

97.4% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Adverum Biotechnologies and Beam Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies02802.80
Beam Therapeutics03302.50

Adverum Biotechnologies currently has a consensus target price of $23.50, suggesting a potential upside of 114.42%. Beam Therapeutics has a consensus target price of $96.00, suggesting a potential upside of 30.63%. Given Adverum Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adverum Biotechnologies is more favorable than Beam Therapeutics.

Summary

Adverum Biotechnologies beats Beam Therapeutics on 11 of the 13 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares Adverum Biotechnologies and Relay Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85
Relay TherapeuticsN/AN/AN/AN/AN/A

Relay Therapeutics has lower revenue, but higher earnings than Adverum Biotechnologies.

Analyst Ratings

This is a summary of current recommendations for Adverum Biotechnologies and Relay Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies02802.80
Relay Therapeutics01502.83

Adverum Biotechnologies currently has a consensus target price of $23.50, suggesting a potential upside of 114.42%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 43.54%. Given Adverum Biotechnologies' higher probable upside, analysts plainly believe Adverum Biotechnologies is more favorable than Relay Therapeutics.

Institutional & Insider Ownership

97.4% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Adverum Biotechnologies and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
Relay TherapeuticsN/AN/AN/A

SpringWorks Therapeutics (NASDAQ:SWTX) and Adverum Biotechnologies (NASDAQ:ADVM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Risk & Volatility

SpringWorks Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500.

Valuation & Earnings

This table compares SpringWorks Therapeutics and Adverum Biotechnologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.52
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85

SpringWorks Therapeutics has higher earnings, but lower revenue than Adverum Biotechnologies. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SpringWorks Therapeutics and Adverum Biotechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00303.00
Adverum Biotechnologies02802.80

SpringWorks Therapeutics currently has a consensus price target of $91.00, suggesting a potential upside of 31.31%. Adverum Biotechnologies has a consensus price target of $23.50, suggesting a potential upside of 114.42%. Given Adverum Biotechnologies' higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than SpringWorks Therapeutics.

Institutional & Insider Ownership

76.3% of SpringWorks Therapeutics shares are held by institutional investors. Comparatively, 97.4% of Adverum Biotechnologies shares are held by institutional investors. 51.2% of SpringWorks Therapeutics shares are held by insiders. Comparatively, 12.4% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SpringWorks Therapeutics and Adverum Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
Adverum BiotechnologiesN/A-32.23%-28.02%

Summary

Adverum Biotechnologies beats SpringWorks Therapeutics on 7 of the 12 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Adverum Biotechnologies (NASDAQ:ADVM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Revolution Medicines and Adverum Biotechnologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million56.31$-47,660,000.00N/AN/A
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85

Revolution Medicines has higher revenue and earnings than Adverum Biotechnologies.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Revolution Medicines and Adverum Biotechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines01402.80
Adverum Biotechnologies02802.80

Revolution Medicines currently has a consensus price target of $50.75, suggesting a potential upside of 19.55%. Adverum Biotechnologies has a consensus price target of $23.50, suggesting a potential upside of 114.42%. Given Adverum Biotechnologies' higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than Revolution Medicines.

Institutional & Insider Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 97.4% of Adverum Biotechnologies shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Revolution Medicines and Adverum Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Adverum BiotechnologiesN/A-32.23%-28.02%

Summary

Adverum Biotechnologies beats Revolution Medicines on 7 of the 10 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Adverum Biotechnologies (NASDAQ:ADVM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NantKwest and Adverum Biotechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Adverum Biotechnologies02802.80

NantKwest currently has a consensus price target of $18.00, suggesting a potential downside of 30.10%. Adverum Biotechnologies has a consensus price target of $23.50, suggesting a potential upside of 114.42%. Given Adverum Biotechnologies' higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500.

Profitability

This table compares NantKwest and Adverum Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Adverum BiotechnologiesN/A-32.23%-28.02%

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 97.4% of Adverum Biotechnologies shares are held by institutional investors. 71.7% of NantKwest shares are held by insiders. Comparatively, 12.4% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares NantKwest and Adverum Biotechnologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0070,166.82$-65,790,000.00($0.70)-36.79
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85

Adverum Biotechnologies has higher revenue and earnings than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

Adverum Biotechnologies beats NantKwest on 9 of the 14 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Adverum Biotechnologies and Editas Medicine, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies02802.80
Editas Medicine34302.00

Adverum Biotechnologies currently has a consensus price target of $23.50, suggesting a potential upside of 114.42%. Editas Medicine has a consensus price target of $49.2222, suggesting a potential upside of 21.96%. Given Adverum Biotechnologies' stronger consensus rating and higher probable upside, research analysts plainly believe Adverum Biotechnologies is more favorable than Editas Medicine.

Volatility & Risk

Adverum Biotechnologies has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500.

Profitability

This table compares Adverum Biotechnologies and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
Editas Medicine-99.62%-26.74%-16.38%

Institutional and Insider Ownership

97.4% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 87.5% of Editas Medicine shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by insiders. Comparatively, 0.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Adverum Biotechnologies and Editas Medicine's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.004,287.38$-64,490,000.00($1.01)-10.85
Editas Medicine$20.53 million132.43$-133,750,000.00($2.68)-15.06

Adverum Biotechnologies has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

Adverum Biotechnologies beats Editas Medicine on 10 of the 14 factors compared between the two stocks.


Adverum Biotechnologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.49-14.0%$4.26 billion$20,000.00-5.23
RLAY
Relay Therapeutics
1.8$39.99-3.5%$3.60 billionN/A0.00
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.30-7.8%$3.39 billionN/A-39.83Analyst Report
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.